ELPA, as part of the Patients’ and Consumers’ Working Party (PCWC) at the European Medicines Agency (EMA) would like to share with you EMA’s recent communications on COVID-19 vaccines:

• First COVID-19 vaccine approved for children aged 12 to 15 in EU

• Insufficient data on use of inhaled corticosteroids to treat COVID-19

• EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19

• Vaxzevria (AstraZeneka): further advice on blood clots and low blood platelets

• More flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccine

All the latest updates on COVID-19 vaccines and treatments are available by clicking here.